U.S. National Institutes of Health
U.S. National Institutes of Health

IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
182041182041Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive BladderCompletedNo Results AvailableOveractive BladderDrug: Darifenacin|Drug: Placebohttps://ClinicalTrials.gov/show/NCT00171184
182042182042A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNo Results AvailableBeta-Thalassemia|HemosiderosisDrug: deferasiroxhttps://ClinicalTrials.gov/show/NCT00171171
182043182043An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast CrisisCompletedNo Results AvailablePhiladelphia Positive Chronic Myeloid Leukemia in Myeloid Blast CrisisDrug: imatinib mesylatehttps://ClinicalTrials.gov/show/NCT00171158
182044182044A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.CompletedNo Results AvailableOveractive Bladder SyndromeDrug: Darifenacin|Drug: Placebohttps://ClinicalTrials.gov/show/NCT00171145
182045182045VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal WomenCompletedNo Results AvailableHypertensionDrug: valsartan|Drug: atenolol|Drug: hydrochlorothiazidehttps://ClinicalTrials.gov/show/NCT00171132
182046182046A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+BenazeprilTerminatedNo Results AvailableHypertension|Diabetic NephropathyDrug: valsartanhttps://ClinicalTrials.gov/show/NCT00171119
182047182047Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart FailureCompletedNo Results AvailableDiastolic Dysfunction, Symptomatic Heart FailureDrug: valsartanhttps://ClinicalTrials.gov/show/NCT00171106
182048182048A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and HypercholesterolemiaCompletedNo Results AvailableHypertension|HypercholesterolemiaDrug: valsartan + simvastatinhttps://ClinicalTrials.gov/show/NCT00171093
182049182049VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term HemodialysisCompletedNo Results AvailableHypertensionDrug: valsartan|Drug: irbesartanhttps://ClinicalTrials.gov/show/NCT00171080
182050182050VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With MicroalbuminuriaCompletedNo Results AvailableHypertensionDrug: valsartan|Drug: lisinoprilhttps://ClinicalTrials.gov/show/NCT00171067
182051182051Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With HypertensionCompletedHas ResultsHypertensionDrug: Valsartan 320 mg|Drug: Amlodipine 10 mg|Drug: Hydrochlorothiazidehttps://ClinicalTrials.gov/show/NCT00171054
182052182052A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of AgeCompletedNo Results AvailableHypertensionDrug: valsartanhttps://ClinicalTrials.gov/show/NCT00171041
182053182053A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have HypertensionCompletedNo Results AvailableHypertensionDrug: valsartanhttps://ClinicalTrials.gov/show/NCT00171028
182054182054VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan MedoxomilCompletedNo Results AvailableHypertensionDrug: valsartan plus hydrochlorothiazidehttps://ClinicalTrials.gov/show/NCT00171015
182055182055Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine AloneCompletedNo Results AvailableHypertensionDrug: valsartan/amlodipinehttps://ClinicalTrials.gov/show/NCT00171002
182056182056Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan AloneCompletedNo Results AvailableHypertensionDrug: valsartan plus hydrochlorothiazidehttps://ClinicalTrials.gov/show/NCT00170989
182057182057A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With HypertensionCompletedNo Results AvailableHYPERTENSIONDrug: valsartan + amlodipinehttps://ClinicalTrials.gov/show/NCT00170976
182058182058Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan AloneCompletedNo Results AvailableHypertensionDrug: valsartan/amlodipinehttps://ClinicalTrials.gov/show/NCT00170963
182059182059Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionTerminatedHas ResultsHypertensionDrug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafterhttps://ClinicalTrials.gov/show/NCT00170950
182060182060A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic SyndromeCompletedNo Results AvailableMetabolic Syndrome|Hypertension|Pre-HypertensionDrug: valsartan plus hydrochlorothiazidehttps://ClinicalTrials.gov/show/NCT00170937
182061182061To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.CompletedNo Results AvailableDiastolic Dysfunction|HypertensionDrug: Valsartanhttps://ClinicalTrials.gov/show/NCT00170924
182062182062Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.CompletedNo Results AvailableOsteoporosisDrug: AAE581https://ClinicalTrials.gov/show/NCT00170911
182063182063Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal PainCompletedNo Results AvailableMusculoskeletal PainDrug: Lumiracoxibhttps://ClinicalTrials.gov/show/NCT00170898
182064182064Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsCompletedNo Results AvailableKidney TransplantationDrug: Everolimushttps://ClinicalTrials.gov/show/NCT00170885
1820651820656 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid ArthritisCompletedNo Results AvailableOsteoarthritis|Rheumatoid ArthritisDrug: Lumiracoxibhttps://ClinicalTrials.gov/show/NCT00170872
182066182066Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant RecipientsCompletedNo Results AvailableHeart TransplantationDrug: Everolimushttps://ClinicalTrials.gov/show/NCT00170859
182067182067ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant RecipientsCompletedHas ResultsRenal TransplantationDrug: Everolimus (RAD001)|Drug: Calcineurin Inhibitors (CNI)|Drug: Mycophenolate acid (MPA)/Azathioprine (AZA)|Drug: Steroidshttps://ClinicalTrials.gov/show/NCT00170846
182068182068Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant PatientsCompletedNo Results AvailableRenal TransplantationDrug: Everolimushttps://ClinicalTrials.gov/show/NCT00170833
182069182069Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free RegimenCompletedNo Results AvailableRenal TransplantationDrug: Everolimushttps://ClinicalTrials.gov/show/NCT00170820
182070182070Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.CompletedNo Results AvailableCardiac TransplantationDrug: Everolimus (RAD001)https://ClinicalTrials.gov/show/NCT00170794

* Görseller ve İçerik tekif hakkına sahip olabilir